Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopeniaÉtienne Crickx(Inserm), Matthieu Mahévas(Délégation Paris 5)Science Translational MedicineApril 14, 202110.1126/scitranslmed.abc3961Cited by 83SaveCiteExport RISWatch citationsRelated PapersMaturation and persistence of the anti-SARS-CoV-2 memory B cell response|Cell|2021|365Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A French Nationwide Study of Ninety‐Two Patients|Arthritis & Rheumatology|2015|69